Intensity Therapeutics (INTS) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Intensity Therapeutics (INTS) has outperformed TScan Therapeutics (TCRX) over the past year, losing 48.4% versus a loss of 89.0%. TScan Therapeutics is the larger company by market cap ($16.1 million vs $11.9 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INTS | TCRX |
|---|---|---|
| Share price | $3.63 | $0.238 |
| Market cap | $11.85M | $16.13M |
| 1-day change | -1.36% | +4.29% |
| YTD return | -64.10% | -76.20% |
| 1-year return | -48.35% | -89.03% |
| 5-year return | — | -96.47% |
| EPS (TTM) | $-3.84 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.50 | $2.57 |
| 52-week low | $3.21 | $0.224 |
| Distance from 52-week high | -91.66% | -90.74% |
| Analyst consensus | none | hold |
| Avg. price target upside | +432.51% | +320.17% |
| Average volume | 25.88K | 784.00K |
| Shares outstanding | 3.26M | 63.50M |
| Employees | 5 | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INTS has outperformed TCRX by 40.7 percentage points over the past year.
About Intensity Therapeutics
INTS stock →Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
INTS vs TCRX FAQ
Which is bigger, Intensity Therapeutics or TScan Therapeutics?
TScan Therapeutics (TCRX) is larger, with a market capitalization of $16.13M compared with $11.85M for Intensity Therapeutics (INTS).
Which stock has performed better over the past year, INTS or TCRX?
INTS returned -48.35% over the past 12 months, compared with -89.03% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are Intensity Therapeutics and TScan Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.